Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy

Karyopharm Therapeutics (KPTI) Announces Proposed $150M Public Offering of Common Stock

March 2, 2020 4:17 PM EST

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock. In addition, Karyopharm also intends to grant the underwriters a 30-day option to purchase up to... More

Karyopharm Therapeutics (KPTI) PT Raised to $35 at Baird

March 2, 2020 8:29 AM EST

Baird analyst Michael Ulz raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $35.00 (from $25.00) while maintaining an Outperform rating following better-than-expected BOSTON study data.

The analyst commented, "This morning, Karyopharm announced highly anticipated Phase 3 results from the BOSTON study of... More